• Uber is creating additional services beyond ride sharing
• The company is looking to the fintech world to find better payment and lending solutions that increase customer loyalty
• Uber is seeking new office space in New York for a team that could exceed 100 workers

Uber Technologies Inc. (NYSE: UBER) is working to go beyond providing convenient and affordable rides from point A to point B. The company is looking toward a future with self-driving technology, urban air transport, food delivery, accessible health care, freight-booking solutions and seamless employee travel. It should come as no surprise, therefore, that a recent CNBC article (http://ibn.fm/wVELa) highlighted the company’s creation of a new fintech outpost in New York in conjunction with an aggressive hiring spree.

Branching out from its hometown of San Francisco to New York provides the company with access to a larger fintech and banking talent pool. According to the article, the move is part of an effort to rise above other ride-sharing programs and increase customer loyalty. Currently, Uber has 93 million active users globally. These riders link credit cards or fund a wallet to pay for services, and Uber is looking to the fintech world to find better payment and lending solutions.

The company has already released fintech products including Uber Cash, Uber Rewards and a co-branded credit card. Solutions such as an Uber bank account are in discussions, though these offerings appear to be years away from becoming a reality.

Uber is actively seeking new office space — as large as 300,000 square feet— in New York to house the several dozen engineers, product managers and other workers on the company’s radar. This New York Uber team could eventually exceed 100 workers.

Uber is continuing to find solutions to create a world in which everyone has safe and easy access to transportation. The company is working to increase its services through inventive programs that address mass transit, provide autonomous driving, streamline payment solutions and develop new technologies and systems for safer rides — all on one tech platform.

For more information, visit the company’s website at www.Uber.com

• Green Hygienics Holdings is in the process of completing the purchase of the Potrero Ranch property near San Diego, California
• The property offers ideal conditions for hemp cultivation, with the potential to harvest two crops per year at an estimated 1,200 to 1,500 pounds of hemp per acre, representing substantial new revenue opportunities
• The U.S. hemp-derived CBD market is now projected to triple in size, reaching $1.3 billion by 2022, while the global industrial hemp market is expected to surpass $10 billion by 2025

Green Hygienics Holdings Inc. (OTCQB: GRYN), a full-scope premium cannabis cultivation company targeting the high-end medical and adult-use recreational markets, is moving to purchase over 824 acres of prime pasture in California’s San Diego County with an eye toward planting hemp – the nation’s newest legal crop. Now in escrow, the ranch property will provide Green Hygienics Holdings with room to grow hemp in California’s rapidly expanding cannabis industry, which reaped approximately $2 billion in total sales in 2018, according to Benzinga (http://ibn.fm/7k2ta).

“Given that there is the potential to harvest 1,200 to 1,500 pounds of hemp per acre, we can produce two crops per year, and the price of hemp is at an average of $50 per pound, this initiative has the potential to produce significant revenues for the Company,” Vice President of Business Development Matt Dole stated in a news release announcing the planned purchase (http://ibn.fm/6ZRA7). “This will also provide a base of operations for several other equally exciting initiatives. We have been working on this property acquisition for a very long time and are excited about the possibilities it opens up for the Company.”

The global industrial hemp market is expected to reach $10.6 billion by 2025, expanding at a compound annual growth rate of 14 percent, according to Grand View Research (http://ibn.fm/nUt0G). New Frontier Data estimates that the hemp-derived CBD market in the United States will grow to a $1.3 billion market by 2022, tripling in size from $390 million in 2018 (http://ibn.fm/wLltx).

Additional potential at the Potrero Ranch property is in the existing outbuildings, spanning 294,000 square feet, which are ideal for use as greenhouses or seed production and storage. The property also includes an updated home, an abundant water supply and soil with the type and pH levels identified as ideal for hemp cultivation.

The 2018 Farm Bill that legalized hemp is expected to transform the American farm industry, creating a new job footprint and bringing an infusion of investment funds to the hemp and cannabis space, according to an article published by CNBC (http://ibn.fm/SfOES).

Hemp, while a cousin to cannabis, has very low traces of THC, the chemical responsible for inducing the “high” associated with marijuana. Hemp is an ancient plant used in products ranging from automotive parts, rope, furniture and textiles to food, beverages, beauty products and construction supplies. Hemp also contains cannabidiol (CBD), which is extracted and infused into products that are showing to be effective in combating anxiety, stress, chronic pain, childhood epilepsy and other ailments, as reported by Harvard Medical School (http://ibn.fm/jdSeG).

For more information, visit the company’s website at www.GreenHygienicsHoldings.com

NOTE TO INVESTORS: The latest news and updates relating to GRYN are available in the company’s newsroom at http://ibn.fm/GRYN

• Blade is a brand new, artificial intelligence-powered underwriting and merchant onboarding solution
• Due to the learning capabilities of AI software, the new solution will gradually become more effective, reducing decision-making time and bringing down the risk of errors
• Demand for artificial intelligence products for use in corporate environments is anticipated to grow rapidly, with financial service companies expected to spend over $11 billion on such products in 2020

Global technology and value-added solutions group Net Element Inc. (NASDAQ: NETE) is launching Blade – an artificial intelligence-based, fully-automated underwriting solution with predictive scoring, a company announcement noted (http://ibn.fm/rT3r4).

Blade is developed for underwriting and onboarding new merchants. The use of such an AI-powered solution brings down potential risks and decision-making time while also enhancing customer experience. The system compiles and analyzes data gathered and assessed based on preset parameters using proprietary algorithms. Additionally, Blade is a smart system that constantly adapts, improving the artificial intelligence mechanism that powers the solution.

The Blade AI scoring system is designed to provide a fast and accurate assessment of risk during the onboarding process. It accounts for a wide range of factors, enabling more effective and data-backed decision-making processes.

Net Element’s system will benefit from continuous updates that will enrich the AI-powered mechanism. This is expected to further speed up decision-making and enhance customer service.

Artificial intelligence for data analysis and corporate use is growing globally. Statistics suggest that financial services companies will spend over $11 billion on AI-powered solutions in 2020 (http://ibn.fm/zSg1Y). These companies can anticipate a high return on investment, since AI is projected to boost GDP in the financial services industry in North America by as much as 10 percent by 2030.

There’s a simple reason why AI-powered solutions deliver such impressive results. In a semi-automated environment, an average account review requires 15 minutes. There are numerous requirements that have to be met in order to ensure regulatory compliance. A review performed through the use of an automated solution like Blade can often takes less than a minute to complete.

Furthermore, whenever an account fails, Blade provides a detailed report about the nature of the problem and the viable solutions.

“AI and machine learning are quickly becoming valuable tools for decision making in the payments ecosystem, particularly in securing e-commerce transactions,” Net Element Vice President of Risk Shawn Brown said in a news release.

Net Element operates a payments-as-a-service transactional and value-added solutions platform. It targets predominantly small and medium-sized companies in the U.S., as well as within select emerging markets.

Through innovation, blockchain technology, cloud-based solutions and productivity tools, Net Element aims to grow transactional value for its clients. One of the primary developments in the Net Element portfolio is Aptito – a cloud-based restaurant and retail point-of-sale solution (http://ibn.fm/WqSaI).

Net Element utilizes an omni-channel platform to deliver flexible services, regardless of the specific market’s regulatory, demographic and banking framework. The strategy has proven to be successful; in 2017, Net Element was included among the fastest-growing companies in North America on Deloitte’s 2017 Technology Fast 500 list.

For more information, visit the company’s website at www.NetElement.com

NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE

• Sproutly’s groundbreaking discovery of naturally water-soluble cannabinoids is projected to be a disruptor in the emerging cannabis beverage and edibles market
• Chief Science Officer Dr. Arup Sen leads the company’s research and development team, which has created 44 different formulations to date
• The company has entered into an exclusive joint venture with Moosehead Breweries Limited to develop and produce nonalcoholic, cannabis-infused beverages

Sproutly Canada Inc. (CSE: SPR) (OTCQB: SRUTF) (FRA: 38G) is advancing its core mission of becoming the leading supplier of water-soluble cannabis solutions and bio-natural oils for beverages and edibles by meeting several key milestones. The company’s chief science officer, Dr. Arup Sen, reviewed recent accomplishments in an interview with InvestorIdeas.com that featured the company’s technological breakthrough in producing and formulating the first natural, truly water-soluble cannabis solution (http://ibn.fm/9aEEi).

“We will be pretty much standing alone in the field of making beverages that will include natural chemicals in their natural state from cannabis and hemp plants,” Sen stated in the interview. “We have created about 44 different formulations, many of which have already gone through the stability testing, both in cans as well as bottles, because, at this point we don’t know how the regulations will turn out. We would prefer glass bottles, because of the clear solution nature of our beverages which will stand out in a glass bottle.”

Deloitte estimates that, as Canada imposes new legislation on October 17, 2019, targeting cannabis and cannabis concentrates in the edibles and beverages sectors, a new $2.7 billion per year market that is expected to generate higher profits for retailers will be created (http://ibn.fm/WouJ5). Deloitte’s report, titled ‘Nurturing new growth: Canada gets ready for Cannabis 2.0’, indicates that the new legislation will likely attract consumers who have been reluctant to try traditional cannabis consumption methods.

“The edibles market alone is estimated to be worth at least $1.6 billion a year in Canada, with cannabis-infused beverages adding a further $529 million,” Jennifer Lee, a partner and Deloitte Canada’s Cannabis National Leader, and Consumer Advisory and Analytics Practice National Leader, stated in the report. “According to our research and stakeholder interviews, much of this economic boost will be on top of current cannabis product spending.”

Sproutly’s acquisition of Infusion Biosciences and its Aqueous Phytorecovery Process (“APP”) technology, which extracts water-soluble forms of cannabinoids for inclusion in beverages and edibles, came with exclusive rights to APP technology in Canada, Australia, Israel, Jamaica and the EU. Sproutly CEO Keith Dolo described the company’s premium offering, Infuz2O, as “the world’s first and only, truly water-soluble cannabis solution” for formulation into beverages.

“APP technology is a low-cost, gentle method to produce Infuz2O, a groundbreaking discovery that delivers the total effects of the strain of cannabis from which it is made; on-set effects start within approximately 5 minutes and dissipate within approximately 90 minutes,” Dolo stated in a news release (http://ibn.fm/izEPc).

A joint venture between Sproutly and OCC Holdings Ltd., an affiliate of Moosehead Breweries Limited, one of Canada’s oldest and largest independent breweries, will utilize the Infuz2O water-soluble cannabis formulation to create a truly natural cannabis beverage experience that serves as an alternative to alcoholic products.

“This partnership with Moosehead marks an important milestone in Sproutly’s mission of delivering a safe and consistent whole plant experience from cannabis, with a lead position in the beverage market,” Dolo stated in a news release announcing the joint venture (http://ibn.fm/n7eAG).

Sproutly executives recently shared details of the APP process at the Canaccord Genuity Third Annual Cannabis Conference and at the Cannastocks 2019 Q1 Investor Conference, both of which were in New York City (http://ibn.fm/VBiWw).

For more information, visit the company’s website at www.Sproutly.ca

NOTE TO INVESTORS: The latest news and updates relating to SRUTF are available in the company’s newsroom at http://ibn.fm/SRUTF

• The company’s recreational cannabis plants and growing processes received organic certification from Pro-Cert Organic Systems Ltd.
• The certification is an important part of the company’s expansion strategy, as the market demand for organic cannabis products is on the upswing
• Organigram recently announced that it has secured a C$140 million credit facility with Bank of Montreal as the lead arranger and agent, which will largely be used to fund the company’s expansion plans and to refinance existing long-term debt

The end of May 2019 marked several exciting developments for Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI), a leading Canadian licensed producer of medicinal and recreational cannabis products.

On May 31, Organigram announced that it has received organic certification for its recreational cannabis plants and growing processes. Pro-Cert, a North American certification body that is accredited to provide certificates under Canadian Organic Standards, worked closely with Organigram during the process.

Consumer demand for organic cannabis is significant, Organigram CEO Greg Engel said in a news release (http://ibn.fm/kYntT). Previously, the company offered select organic strains among its Organigram medical cannabis products. The extended recreational organic offerings are expected to please recreational consumers who are interested in organically certified products, Engel concluded.

The certification strengthens Organigram’s product offerings. Additionally, it complements the EcoCert certification that currently applies to Organigram’s medical products. Receiving the Pro-Cert certification also facilitates the company’s planned launch of ANKR Organics – a line of organic flower and edible extract oils. ANKR’s launch is anticipated later in 2019 within select Canadian markets.

Organigram has always prioritized the production of high quality, indoor-grown cannabis products for patients and adult recreational users in Canada. A focus on extending Organigram’s global footprint is also guiding the company’s strategic efforts.

As part of its expansion strategy, Organigram also announced the closing of a C$140 million credit facility with Bank of Montreal (http://ibn.fm/mckuw). The facility consists of a C$115 million term loan and a C$25 million revolving credit facility. Both of these mature in May 2022.

“The closing of this credit facility reflects BMO’s and the syndicate lenders’ vote of confidence in our management team, ability to deliver financial results, and investment in our world-class Moncton campus,” Engel said in a news release.

Organigram is always looking to optimize its capital structure and reduce the cost of capital, Organigram CFO Paolo De Luca added. The decision not to access public capital markets is aimed at avoiding shareholder dilution, he noted.

Both facilities are secured by Organigram assets, primarily consisting of the Moncton campus production facility. The final constructed and licensed facility is projected to be able to produce the dried flower equivalent cannabis of 113,000 kilograms (249,000 lbs.) per year. Construction is expected to be completed by the end of 2019. The Moncton facility will also house innovative manufacturing equipment, including the previously announced C$15 million infrastructure investment to produce world class infused chocolate products.

The proceeds from the term loan will be used to fund phases four and five of the Moncton campus expansion. In addition, funds will be used to refinance Organigram’s existing long-term debt with Farm Credit Canada.

For more information, visit the company’s website at www.Organigram.ca

NOTE TO INVESTORS: The latest news and updates relating to OGI are available in the company’s newsroom at http://ibn.fm/OGRMF

• Geyser Brands announced an innovative pet care product through its recent acquisition target
• The burgeoning pet care market has seen prominent growth
• The company plans to utilize NanoFusion technology in WildTails’ product development

Geyser Brands Inc. (TSX.V: GYSR), a leading consumer health care company, recently announced the world’s first hemp-infused, freeze-dried pet food through its acquisition target, Solace Management Group Inc.

The company’s announcement aligns with its vision to help people and their pets worldwide with a range of discomfort and health care issues (http://ibn.fm/iXmif), and to support innovation through R&D and product development. This latest new brand, WildTails, joins the success of Solace’s impressive Apawthecary Pets brand. WildTails’ freeze-dried infused products will be available in single-ingredient servings of white fish, beef and chicken (http://ibn.fm/3ajFl). As the company looks to the completion of its Solace acquisition, Geyser Brands is negotiating order-and-distribution contracts, which are expected to be announced in Q3 2019; several of those will be in Asia.

The pet care market has seen prominent growth due to several factors, including a rise in pet adoption and a swelling middle class with an evolving health and wellness consciousness. Customers are demanding high-quality health products for both themselves and their domesticated companions, and the pet care market is estimated to bloom in the upcoming years.

Once the Solace acquisition is complete, Geyser Brands anticipates that WildTails’ products will utilize its proprietary NanoFusion technology to infuse hemp into proteins. By infusing before freeze drying, Geyser will be able to offer a unique product when compared with competitors’ brands, which use the more common practice of coating products with oils after freeze drying (http://ibn.fm/yseA7). In markets without a legal CBD environment, WildTails will be produced with hemp seed oil, and, in markets with established regulations and a clear compliance pathway, CBD can be used as a value-added ingredient.

Geyser Brands has pioneered an advanced delivery system that improves the efficacy of hemp product absorption. Utilizing its NanoFusion technology, Geyser Brands’ products offer improved skin penetration and longer shelf life and molecule stability.

The acquisition portfolio already features a variety of diverse brands, including baked hemp-infused pet products to help mitigate anxiety and pain; these products already utilize NanoFusion to ensure proper dosage control. Outside of the pet-wellness sector, the company also features the Apothecary Naturals brand hemp terpene pain cream with optimal skin permeation, Prohibition Cold Brew Mocha designed with water-soluble hemp molecules and Apothecary health products, which promise fast-action and high bioavailability in a spray formation.

For more information, visit the company’s website at www.GeyserBrands.com

NOTE TO INVESTORS: The latest news and updates relating to GYSR are available in the company’s newsroom at http://ibn.fm/GYSR

• The exclusive partnership with PAX Labs will enable Supreme Cannabis and its subsidiary, 7ACRES, to access the highly lucrative vaporizer market
• 7ACRES will become one of only four companies to supply cannabis oil pods for the PAX Era
• The partnership provides a significant strategic advantage to Supreme Cannabis due to PAX’s market penetration; currently, the company has over 1.5 million devices sold worldwide

A partnership between The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) and PAX Labs Inc. will enable Supreme to become the foundational brand partner and supplier for premium vaporizer the PAX Era in Canada.

Pending the legalization of vaporization products in the country, Supreme Cannabis will become one of only four initial supply PAX Era partners, the company announced in a press release (http://ibn.fm/u6di5). This opportunity enables Supreme Cannabis to enter the lucrative vaporization product market. The company’s wholly owned subsidiary, 7ACRES, has been chosen as an initial partner that will create cannabis oil pods for the PAX Era.

PAX Labs is a market leader in the field of vaporizer products. Set up in 2007, the company aims to create a responsible and personalized cannabis experience for its users. In 2018, PAX became an award-winning consumer technology brand due to its focus on design and innovation.

The PAX Era is a cannabis oil vape pen. Its delivery method is precise and innovative, allowing for control over concentration, flavor, potency and temperature. Currently, PAX has over 1.5 million devices sold worldwide. A partnership with such a well-established entity is expected to provide Supreme Cannabis with opportunities for a quick and effective market.

“Supreme Cannabis is excited to be partnering with PAX to provide consumers with the ultimate vaporizing experience. Together, we expect to deliver 7ACRES’ multi-award winning flower extracted into oils exclusively for use in North America’s best-selling premium vaporizer, the PAX Era,” Supreme Cannabis CEO Navdeep Dhaliwal stated in a news release.

7ACRES is a leading Canadian brand in the high-end cannabis field. Expansion to new product categories is currently being undertaken while 7ACRES focuses on maintaining its high standards and quality, to which discerning customers have become accustomed, according to Dhaliwal.

As per the terms of the agreement, the 7ACRES vaporizer oil will be sold exclusively for use with the PAX Era. The new 7ACRES PAX Era pods will be sold in every jurisdiction where Supreme Cannabis has provincial supply agreements. It’s also possible that Supreme Cannabis will start creating cannabis pods for the PAX Era under a different brand.

The Supreme Cannabis Company has developed a global, diversified portfolio of cannabis companies, products and brands. The company established itself as a fast growing, premium cannabis and plant-driven lifestyle entity through a focus on sustainable growth and the development of high-quality products.

7ACRES, the Supreme Cannabis Company’s wholly owned subsidiary, is an award-winning brand that grows high-end cannabis. The company provides hand-crafted cannabis flower to discerning customers. Products are characterized by superior genetics, aroma, appearance, size and texture.

For more information, visit the company’s website at www.Supreme.ca

NOTE TO INVESTORS: The latest news and updates relating to SPRWF are available in the company’s newsroom at http://ibn.fm/SPRWF

• SGSI sees a dynamic market opportunity in new 5G site projects
• A spike in installation demand combined with limited qualified services firms could result in a financial opportunity for SGSI
• The company reported positive income from operations during the first quarter of 2019

Spectrum Global Solutions Inc. (OTCQB: SGSI) says that its bundling of services and the low number of qualified services firms in the growing telecommunications market helped drive higher revenues and growth in its margin potential on projects in the first quarter of 2019 (http://ibn.fm/XUSUd).

Notably, SGSI reported first quarter revenues of $11,335,732 for the three months ended March 31, 2019, as compared to $4,327,764 for the first quarter of 2018 (http://ibn.fm/6G25a). First quarter numbers also showed SGSI achieving its first quarterly positive income from operations of $14,699 in Q1 2019, as compared to a loss from operations of $743,491 for the comparable period in 2018.

The combined gross profit reported in Q1 from subsidiaries acquired in April 2017, February 2018 and January 2019 was $2,511,567, marking a 22.2 percent gross profit increase. By comparison, in the first quarter of 2018, the company’s gross profit was $543,244.

SGSI sees market growth in future 5G implementation from telecom companies, as well as ongoing 4G network upgrades. The company has positioned itself to gain more market share and will seek to maximize cross-selling opportunities by leveraging services and relationships with clients of operating subsidiaries. The peak in market installation demand and low number of qualified services firms could result in SGSI expanding 2019 revenues, driven by strategic, accretive acquisitions and organic growth.

SGSI is a leading provider of telecommunications engineering and infrastructure services in the United States, Puerto Rico, Canada, Guam and the Caribbean. The company sees an intriguing opportunity as new 5G sites expand wireless coverage and 4G sites continue to require maintenance and upgrades. SGSI subsidiaries include AW Solutions, ADEX TNS and Tropical Communications Inc.

SGSI is a single-source provider of wireless and wireline network infrastructure and professional service solutions to the service provider (carrier) and corporate enterprise markets. The company builds and services end-to-end communication networks (http://ibn.fm/07Yl7).

For more information, visit the company’s website at www.SpectrumGlobalSolutions.com

NOTE TO INVESTORS: The latest news and updates relating to SGSI are available in the company’s newsroom at http://ibn.fm/SGSI

• Earth Science Tech is a biotechnology company offering high-grade cannabinoids
• ETST has diverse subsidiaries that promote the company’s role as a leader in the CBD sector
• Earth Science Tech has various partnerships and distribution agreements in place

Earth Science Tech Inc. (OTCQB: ETST) operates in the hemp cannabinoid, nutraceutical, pharmaceutical and medical device research and development fields. A biotechnology company headquartered in Doral, Florida, ETST markets high purity and quality full-spectrum cannabinoids. The company’s wholly owned subsidiaries – including Earth Science Pharmaceutical Inc., Cannabis Therapeutics Inc. and Canna Inno Laboratories Inc. – concentrate on developing Earth Science Tech’s role as a worldwide leader in the CBD sector.

The company’s management team consists of experienced industry experts from the nutraceuticals, dietary supplement and life sciences fields. Earth Science Tech is developing new products and has secured several partnerships, with strategic plans to extend its footprint within the medical cannabis market. These partnerships will enable the company to develop new and novel cannabinoid-based pharmaceutical and nutraceutical products (http://ibn.fm/P4T2M).

Wholly owned subsidiary Earth Science Pharmaceutical develops low-cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and diseases (STIs). The executive team of Earth Science Pharma has years of scientific, medical and business experience in the health, research and manufacturing fields. The subsidiary is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.

Earth Science Pharma’s first medical device is MSN-2, a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Tech is advancing clinical testing of MSN-2 via a collaborative agreement with Laboratories BNK Canada (http://ibn.fm/Ckn54).

Wholly owned subsidiary Cannabis Therapeutics is working to take a leadership role in the development of new, cutting-edge, cannabinoid-based pharmaceutical and nutraceutical products. The company is invested in research and development to explore and harness the medicinal power of cannabidiol. Cannabis Therapeutics is also working to integrate the CBD molecule with existing generic drug molecules. The company’s mission is to help change the health care landscape by introducing its proprietary cannabis/cannabinoid-based products made for the global pharmaceutical and retail consumer markets.

Established in 2017, Canna Inno Laboratories is Earth Science Tech’s Canadian subsidiary, based in Montreal, Québec. The company’s mandate is to give ETST a foothold in Québec and provide the company with access to government grants offered to innovators in the pharmaceutical industry. One grant has been approved so far.

Earth Science Tech’s medical and industrial hemp products are made from high-grade, full-spectrum cannabinoids that are extracted using the supercritical CO2 liquid process. All of the company’s full-spectrum cannabinoids are mixed in coconut MCT oil to ensure the best delivery and absorption, and its offerings include CBD, CBDa, CBG, CBGa, CBN, CBC and CBDV; the cannabinoids also contain terpenoids, aminos, omegas, saponins and flavonoids.

Earth Science Tech has entered into agreements with CannaBiz and Desert Sun Distribution (http://ibn.fm/xknKJ) for the distribution of the company’s high-grade, full-spectrum cannabinoids line throughout pharmacies, chiropractors, dispensaries, athletic clubs and clinics in the United States.

“We see tremendous synergy between our CBD line and the health care practitioner and pharmacy spaces,” ETST Chief Sales Officer David Barbash stated in a news release. “The distribution agreements with CannaBiz and Desert Sun Distribution, while important, are only a fraction of the opportunities we see for our CBD products.”

Earth Science Tech continues to develop its diverse portfolio and pipeline. The company offers investors the opportunity to be part of the burgeoning cannabinoid-based pharmaceutical and nutraceutical products market as it expands its role as a leader in different sectors. Earth Science Tech remains dedicated to developing leading-edge pharmaceutical and medical device offerings.

For more information, visit the company’s website at www.EarthScienceTech.com

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at http://ibn.fm/ETST

• INmune Bio is at the vanguard of reprogramming the innate immune system for the treatment of disease
• The company’s focus is on modulating components of the innate immune system to treat cancer and Alzheimer’s disease
• INmune Bio’s drug candidates include INKmune, INB03 and XPro1595

INmune Bio Inc. (NASDAQ: INMB) is a diversified, clinical-stage biotechnology company headquartered in La Jolla, California. The company is hoping to develop new immunotherapies that reprogram patients’ innate immune systems to allow the immune systems to fight cancer and Alzheimer’s disease. INmune drug candidates INKmune and INB03 may be used to treat cancer, while XPro1595 targets neuroinflammation as a cause of Alzheimer’s disease.

INmune Bio’s vision is to become the leader in reprogramming the innate immune system for the treatment of disease. Innate is an immediate, nonspecific, initial response that serves as a first line of defense against infection and cancer. Most drug-development programs concentrate on the adaptive immune response and ignore innate immunity. INmune Bio harnesses the innate immune system with a targeted biomarker approach.

The company’s INKmune drug is a biologic therapy. INKmune primes NK cells to eliminate minimal residual disease, which is a major cause of cancer relapse and death. NK cells play a vital role in preventing cancer. Later this year, the company expects to begin enrolling patients in a phase I/II trial for women with relapsed refractory ovarian cancer.

INKmune is delivered by simple IV infusion, allowing for the delivery of critical priming signals to patients’ resting NK cells. Once in the system, INKmune encounters resting NK cells. The interaction converts NK cells to primed NK cell (“PiNK”), much like an on-off switch. PiNK then remain primed until they contact and kill cancer cells (http://ibn.fm/zb0GM).

INmune Bio’s INB03 is a protein biologic. The company believes that INB03 could have numerous beneficial effects in patients with cancer. INmune Bio’s initial emphasis is on its ability to inhibit the proliferation and function of myeloid-derived suppressor cells (“MDSC”). By preventing the proliferation and function of MDSC, the company believes that patients will have a stronger immune response to cancer cells.

INmune Bio also believes that INB03 treatment may help patients better respond to other cancer treatments, including immunotherapy. INB03 is a PEGylated protein therapeutic administered as a once-weekly subcutaneous injection, similar to an insulin shot (http://ibn.fm/Dql3j). This summer, the INB03 program will transition into a combination therapy clinical program to prepare for a phase II trial to research patients’ resistance to checkpoint inhibitors because of increased MDSC.

The company’s XPro1595 is a protein biologic that targets soluble TNF (“sTNF”). XPro1595 may trigger many beneficial effects in patients with Alzheimer’s disease by reducing neuroinflammation. XPro1595 targets the microglial immune cells of the brain, which are responsible for neuroinflammation and are activated in many Alzheimer’s disease patients.

INmune Bio continues to develop its product platforms that use a precision therapy approach. The company offers investors the potential for significant ROI as it targets large markets with unmet needs. With its programs in oncology and neurodegenerative disease, INmune Bio is focusing on multiple opportunities that provide sum-of-parts value.

For more information, visit the company’s website at www.INmuneBio.com

NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB